By selecting the right treatment adjuvant to tumor profile, PREDICT modelling estimated that most post‐surgery patients (85.7%, ER+; 100%, ER‐) would have clinically relevant overall survival (OS) benefit. Here, ESR1 is linked to neoplasm.